Data on plasma tumour and metabolism related proteins’ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension

Research output: Contribution to journalArticlepeer-review

Abstract

The data in the current paper constitutes supplementary material to our article entitled “Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertension” Ahmed et al. (2021). The study investigated 69 plasma tumour- and metabolism related proteins in healthy controls (n = 20) and in 115 patients of whom 48 had pulmonary arterial hypertension (PAH; n = 48) and 67 with left heart failure with pulmonary hypertension (LHF-PH) [heart failure with- preserved ejection fraction-PH (HFpEF-PH; n = 31) and reduced ejection fraction-PH (HFrEF-PH; n = 36)]. The haemodynamic data were obtained with right heart catheterization, and clinical data from medical records. The present article describe the plasma levels of tumour- and metabolism related proteins, analyzed with proximity extension assay, along with their uni- and multivariable diagnostic and prognostic potential. High sRAGE levels univariably emerged as a negative prognostic marker in LHF-PH.

Original languageEnglish
Article number107747
JournalData in Brief
Volume40
DOIs
Publication statusPublished - 2022 Feb

Subject classification (UKÄ)

  • Cardiac and Cardiovascular Systems

Free keywords

  • Cancer
  • Haemodynamics
  • HFpEF
  • PAH
  • Prognosis
  • Proteomics
  • Pulmonary hypertension
  • Pulmonary hypertension due to left heart disease

Fingerprint

Dive into the research topics of 'Data on plasma tumour and metabolism related proteins’ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension'. Together they form a unique fingerprint.

Cite this